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ABSTRACT
Mutations in the components of the minor spliceosome underlie several human diseases. A subset of patients with isolated growth
hormone deficiency (IGHD) harbors mutations in the RNPC3 gene, which encodes the minor spliceosome-specific U11/U12-65K
protein. Although a previous study showed that IGHD patient cells have defects in U12-type intron recognition, the biochemical
effects of these mutations on the 65K protein have not been characterized. Here, we show that a proline-to-threonine missense
mutation (P474T) and a nonsense mutation (R502X) in the C-terminal RNA recognition motif (C-RRM) of the 65K protein impair
the binding of 65K to U12 and U6atac snRNAs. We further show that the nonsense allele is targeted to the nonsense-mediated
decay (NMD) pathway, but in an isoform-specific manner, with the nuclear-retained 65K long-3′UTR isoform escaping the
NMD pathway. In contrast, the missense P474T mutation leads, in addition to the RNA-binding defect, to a partial defect in
the folding of the C-RRM and reduced stability of the full-length protein, thus reducing the formation of U11/U12 di-snRNP
complexes. We propose that both the C-RRM folding defect and NMD-mediated decrease in the levels of the U11/U12-65K
protein reduce formation of the U12-type intron recognition complex and missplicing of a subset of minor introns leading to
pituitary hypoplasia and a subsequent defect in growth hormone secretion.
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INTRODUCTION
Pre-mRNA splicing is carried out by a complex machinery
composed of small nuclear RNAs and >170 proteins (Will
and Lührmann 2011). The extensive array of factors involved
in splicing and the highly complex splicing code embedded in
the RNA sequence allows fine-tuned regulation of the splic-
ing process, but makes the system vulnerable to perturba-
tions. Indeed, defects in splicing, arising from mutations in
either splicing regulatory sequences or, more rarely, in the
components of the splicing machinery, are a major cause of
human genetic disease (Singh and Cooper 2012).
Most introns are excised by the major, U2-dependent spli-
ceosome, but a small subset (>0.5%) containing highly con-
served 5′ splice sites (5′ss) and branch point sequences (BPS)
are removed by the minor, U12-dependent spliceosome
(Turunen et al. 2013a). Both spliceosomes are composed of
five small nuclear RNA (snRNA) molecules, which, upon as-
sociation with protein components, form small nuclear ribo-
nucleoprotein (snRNP) particles. Additionally, numerous
non-snRNP proteins associate with the spliceosome compo-
nents during the splicing process (Hastings and Krainer 2001;
Wahl et al. 2009; Matera and Wang 2014). The two spliceo-
somes share the U5 snRNP, while the remaining four snRNPs
in each spliceosome are distinct but functionally analogous,
with U11, U12, U4atac and U6atac of the minor spliceosome
replacing the respective U1, U2, U4 and U6 in the major spli-
ceosome (Hall and Padgett 1996; Tarn and Steitz 1996a,b;
Kolossova and Padgett 1997; Yu and Steitz 1997). While
the overall assembly and catalytic steps of intron removal
are very similar between the two spliceosomes (Tarn and
Steitz 1996a,b; Frilander and Steitz 2001), there is a signifi-
cant difference in the intron recognition step, which for mi-
nor introns is carried out by a preformed U11/U12 di-snRNP
complex (Wassarman and Steitz 1992; Golas et al. 2005) that
cooperatively recognizes the 5′ss and BPS (Frilander and
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Steitz 1999). In contrast, the 5′ss and BPS of the major in-
trons are recognized independently by individual U1 and
U2 snRNPs. This functional difference is reflected in the
composition of the U11/U12 di-snRNP, which, in addition
to the two unique snRNAs, also contains seven protein spe-
cies that are unique to the minor spliceosome (Will et al.
1999, 2004), while the other proteins associated with the mi-
nor spliceosome are shared with the major spliceosome
(Hastings and Krainer 2001; Schneider et al. 2002 ).
Several studies in the past few years have implicated minor
spliceosome dysfunction in human diseases (for review, see
Verma et al. 2018). Mutations in the specific components of
the minor spliceosome have been found to cause four rare
congenital disorders, Microcephalic Osteodysplastic Primor-
dial Dwarfism type I/Taybi-Linder syndrome (MOPD I/
TALS) (Edery et al. 2011; He et al. 2011), Roifman syndrome
(RFMN) (Merico et al. 2015), early-onset cerebellar ataxia
(EOCA) (Elsaid et al. 2017) and a subset of isolated growth
hormone deficiency cases (IGHD) (Argente et al. 2014;
Guceva et al. 2015). The first three diseases result frommuta-
tions in the snRNA components of the minor spliceosome,
specifically theU4atac snRNA inMOPD I/TALS andRoifman
syndrome, and U12 snRNA in cerebellar ataxia, while IGHD
is caused by mutations in a gene encoding the minor spliceo-
some-specific U11/U12-65K protein. Furthermore, somatic
mutations in the ZRSR2 gene, encoding the Urp protein of
the U11/U12 di-snRNP that is involved in 3′ splice site
(3′ss) recognition (Shen et al. 2010), underlie a subset ofmye-
lodysplastic syndrome (MDS) cases (Yoshida et al. 2011;
Madan et al. 2015). Finally, recent studies also suggest a role
for minor spliceosome dysfunction in the motor neuron dis-
eases spinal muscular atrophy (SMA) and amyotrophic lateral
sclerosis (ALS) (Doktor et al. 2016; Reber et al. 2016).
TheRNPC3 genemutated in IGHDpatients encodes an in-
tegral 65K protein component of the U11/U12 di-snRNP
(Will et al. 2004). It contains two RNA recognition motifs
(RRMs), of which the carboxy-terminal RRM (C-RRM) is
used to bind to the 3′ terminal stem–loop of the U12
snRNA (Benecke et al. 2005). Additionally, a recent work
demonstrated that the C-RRM also interacts with the near-
identical 3′ terminal stem–loop of the U6atac snRNA (Singh
et al. 2016).Within the U11/U12 di-snRNP the amino-termi-
nal part of the 65K protein in turn interacts with the U11
snRNP-specific 59K protein (Benecke et al. 2005), which itself
interacts with U11-48K, a protein that participates in recogni-
tion of the U12-type 5′ splice site with U11 snRNA (Turunen
et al. 2008; Tidow et al. 2009). Thus, the U11/U12-65K pro-
tein has a central role in a protein–protein interaction net-
work that connects the individual U11 and U12 snRNPs
that function in the recognition of the 5′ and 3′ ends of the
U12-type introns, respectively. Furthermore, these interac-
tions are important for the stability of the di-snRNP complex
(Turunen et al. 2008; Argente et al. 2014), are conserved from
plants to mammals (Park et al. 2016) and provide an impor-
tant regulatory target as the levels of U11-48K and U11/U12-
65K proteins are both regulated at the post-transcriptional
level by evolutionarily highly conserved feedbackor cross-reg-
ulation mechanism (Verbeeren et al. 2010, 2017; Turunen
et al. 2013b; Niemelä et al. 2015).
Presently, two recessive patient mutations have been re-
ported to associate with IGHD: a proline-to-threonine mis-
sense mutation (P474T) within the C-RRM and a nonsense
mutation (R502X) that deletes 16 residues (502–517) from
the carboxyl terminus of the protein, immediately down-
stream from the core C-RRM domain (Fig. 1A; Argente et al.
2014). Patients are compound heterozygotes for the two mu-
tations and show various defects in the splicing of U12-type
introns. Besides the reduced stability of the di-snRNP ob-
served in the patient cells, detailed understanding of the mo-
lecular consequences of the mutations is lacking. Here, we
have carried out biochemical and structural analyses of the
IGHD-causing 65Kmutations.We found that the P474Tmu-
tation leads to significant unfolding of the C-RRM and a con-
comitant, approximately threefold drop in its affinity to U12
and U6atac snRNAs. The mRNA carrying the R502X muta-
tion is efficiently targeted by the nonsense-mediated decay
(NMD) machinery in patient cells and the truncated protein
is thus likely to be expressed at a negligible level. Furthermore,
analysis of the R502Xmutant protein revealed that removal of
the flexible tail region of the C-RRM leads to a near-complete
loss of RNA-binding activity. In the cellular context, bothmu-
tants associate with U11/U12 di-snRNPs less efficiently than
the wild-type protein, and di-snRNP complexes formed by
the R502X mutant are additionally unstable. In contrast,
our data suggest that the defectively folded P474T C-RRM
may be stabilized upon incorporation into the di-snRNP
complex, allowing formation of stable di-snRNPs, thus po-
tentially explaining the relativelymild pathological phenotype
observed with the patients.
RESULTS
IGHD-causing mutations in the 65K protein
lead to impaired RNA binding
To address the impact of IGHD-causing mutations within
the 65K protein on binding of the U12 or U6atac snRNAs
in vitro, we carried out RNA-binding assays using recombi-
nant wild-type (WT) or mutant (P474T or R502X) 65K C-
RRM and 32P-labeled short RNA hairpin substrates described
earlier (Fig. 1A; Benecke et al. 2005; Singh et al. 2016). As the
untagged P474T-mutant RRM is stable in soluble form under
RNA-binding conditions for only a short time after the tag
cleavage, the in vitro binding assays were carried out using
tagged proteins, while untagged proteins were used for all
other experiments (Supplemental Fig. S1). Short RNA hair-
pins corresponding to U12 snRNA nucleotides 109–125
and U6atac nucleotides 92–108 were used as ligands and a
hairpin with a sequence complementary to the U12 hairpin
was used as a control for nonspecific binding (Fig. 1A).
U11/U12-65K mutations in IGHD
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RNA and protein samples were incubated in conditions de-
scribed earlier (Benecke et al. 2005). The resulting RNA–pro-
tein complexes were either crosslinked using UV light,
digested with RNase A and run on an SDS-polyacrylamide
gel (UV crosslinking assay) or resolved from free RNA on a
native polyacrylamide gel (EMSA).
UV treatment of increasing amounts of wild-type C-RRM
in the presence of the labeled U12 oligonucleotide resulted in
the appearance of a band of ∼45 kDa that was not detected in
the absence of protein (Fig. 1B, lane 1) or without UV treat-
ment (lane 2). Compared to the wild-type protein, the
P474T mutant showed reduced crosslink formation (lanes 3
−6 and 8−11), while no crosslinking was observed with the
R502X mutant in the protein concentration range used in
the assay (lanes 13−16). Next, we carried out electrophoretic
mobility shift assays to quantitatively analyze the effect of the
mutations on RNA binding (Fig. 1C–E; Supplemental Fig.
S2). First, we tested whether the GST-tagged wild-type
RRM binds RNAwith similar affinity as the untagged protein
and found the KDs to be similar (Supplemental Fig. S2A).
Compared to the wild-type protein (KD = 0.8 µM), the
P474Tmutant showed approximately threefold reduced bind-
ing to the U12 oligo (KD = 3.1 µM), while the R502Xmutation
led to essentially complete loss of binding (Fig. 1C,E). Even
when significantly higher protein concentrations were used,
no specific complex formation could be observed for R502X
(Supplemental Fig. S2B) under the experimental conditions.
Next, we tested the effect of 65K mutations on U6atac
snRNA binding. EMSA with an U6atac-specific hairpin re-
vealed approximately threefold weaker affinity to the WT C-
RRM(Fig. 1D,E). Importantly, the relative difference between
WT and P474T in binding to U12 and U6atac hairpins re-
mained the same, as we found that the P474T mutation leads
to approximately threefold reduction in U6atac binding [KD
(WT) = 2.5 µM, KD (P474T) = 7.3 µM; Fig. 1D,E], similarly
asobservedwith theU12 stem–loop. Furthermore, nobinding
of the U6atac stem–loop was observed for the R502X mutant
(Fig. 1D; Supplemental Fig. S2B).
Mutated 65K proteins can bind to U11 snRNP in vivo
To ask if themutated 65K proteins can be incorporated into the
U11/U12 di-snRNP or the individual U11 or U12 snRNPs, we
next expressed V5-tagged full-length 65K proteins (either WT
protein or P474T or R502Xmutant) in HeLa cells. After cell ly-
sis and immunoprecipitation (IP) with anti-V5 antibody, we
analyzed the association of the 65K protein with U11 and
U12 snRNAs by northern blotting. We found that the WT
V5-65K protein showed a robust co-IP of both U11 and U12
snRNAs, suggesting that the V5-tagged protein can be incorpo-
rated to the U11/U12 di-snRNP (Fig. 2A, lane 3). In contrast,
both mutants showed a clear reduction in the levels of co-IP
of both U11 and U12 snRNAs (Fig. 2A, lanes 4–5 and Fig.
2B). The difference between the two mutants was that the
P474T mutation affects the association of both U11 and U12
snRNA equally, while with the R502X mutation the co-IP of
U12 snRNA is very inefficient. Interestingly, comparison to
western analysis of the V5-tagged proteins revealed a correlation
between co-IP and 65K levels (Fig. 2B), while the mRNA levels
of the V5-tagged proteins (as analyzed by RT-PCR) were equal
between the three different constructs (Fig. 2A).
Together the results suggest that in the context of full-
length 65K protein both mutations may reduce the stability
of the protein. However, the correlation between U11
snRNA co-IP efficiency and V5-tagged protein levels suggests
that the mutated proteins may be stabilized upon binding to
U11 snRNP, which presumably takes place via theN-terminal
RRM interacting with the U11-59K protein as previously de-
scribed (Benecke et al. 2005). In contrast, the efficiency ofU12
snRNA co-IP is consistent with the effect of the mutations on
U12 binding in vitro (Fig. 1), and suggests that the two mu-
tants have differential effects on U11/U12 di-snRNP stability.
Destabilization, particularly by the R502X mutation, could
potentially lead to a dominant negative effect that could
decrease the efficiency of the splicing of U12-type introns.
However, we failed to detect any increased minor intron re-
tention (Supplemental Fig. S3A) or cryptic splice site activa-
tion (Supplemental Fig. S3B) upon expression of either V5-
taggedmutated protein, while the splicing defects were readily
observed after knockdown of specific U11/U12 di-snRNP
components (Supplemental Fig. S3B, cf. lanes 2–4 and 7–9).
The R502X mutation leads to isoform-specific
nonsense-mediated decay
The position of the 1504C>T (p. R502X) mutation ∼50 bp
upstream of the stop codon in the penultimate exon
FIGURE 1. P474T and R502Xmutations in 65K lead to impaired U12 and U6atac binding. (A) Protein constructs and RNA oligonucleotides used in
this study. (Left) Domain structures of the full-length 65K protein and the GST-tagged and untagged protein constructs are shown. Locations of the
P474T and R502X mutations are also indicated. (Right) Secondary structures of the control, U12 and U6atac oligonucleotides used in this study. (B)
Ultraviolet crosslinking of wild-type and mutant 65K C-RRM to a U12 oligonucleotide. Indicated concentrations of GST-tagged protein constructs
(WT, P474T or R502X) shown in A, were incubated with a 32P-labeled U12 oligo, crosslinked with UV, digested with RNase A and run on a SDS-
polyacrylamide gel. “No UV” control samples were otherwise treated identically, but UV treatment was omitted. (C) EMSA analysis of the interaction
of wild-type and mutant 65K C-RRMs with the U12 oligonucleotide. RNA–protein complexes were formed by incubating the labeled U12 oligonu-
cleotide with varying concentrations of the indicated GST-tagged protein. Subsequently, complexes were resolved from the free unbound RNA on a
native polyacrylamide gel. (D) EMSA analysis of the interaction of wild-type and mutant 65K C-RRMwith U6atac. The experiment was carried out as
in C, but using a U6atac oligonucleotide. (E) Dissociation constants and binding curves determined from EMSA experiments. Dissociation constants
were determined by quantification of EMSA gels and nonlinear regression using data from three replicate EMSA experiments. Values in brackets in-
dicate 95% confidence intervals.
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(Fig. 3A) suggests that this allele may be targeted by the cyto-
plasmic nonsense-mediated decay (NMD) pathway. To ask if
this is indeed the case, we treated lymphoblastoid cell lines
derived from two control individuals and two IGHD patients
(Argente et al. 2014) either with translation blocker cyclohex-
imide (CHX) that is expected to stabilize NMD targets, or
with DMSO as a control. However, the downstream analysis
is complicated by the crossregulatory pathway targeting 65K
mRNA that leads to the formation of two mRNA isoforms
with different 3′UTR sequences (Verbeeren et al. 2010). Of
these, only the transcript containing short 3′UTR (Fig. 2A)
is cytoplasmic and accessible to translation machinery, while
the transcript with long 3′UTR is retained in the nucleus
(Verbeeren et al. 2017). Therefore, it was necessary to analyze
the effect of the CHX treatment for the two isoforms sepa-
rately, first using RT-PCR primers specific for the short-
3′UTR and long-3′UTR isoforms (Fig. 3A) and then subse-
quently analyzing the PCR products with mismatch cleavage
(Surveyor) assay (Fig. 3B) and Sanger sequencing (Fig. 3C).
The cleavage pattern of the annealed PCR products in the
Surveyor assay not only confirms the presence of two mis-
match mutations in IGHD patient cells (Fig. 3B), but also
provides evidence that one of the transcripts is targeted by
the NMDmachinery. Specifically, the CHX-treated short iso-
form reactions (Fig. 3B, lanes 5–8) show an increase of the
cleaved products, suggesting that one of the transcripts is be-
ing stabilized due to block in translation. Consistently, direct
sequencing of the PCR products shows an underrepresenta-
tion of the WT allele in the position of the P474T mutation
(Fig. 3C, panel C1) and a similar underrepresentation of
the nonsense allele in the position of the R502X mutation
(Fig. 3C, panel C4). After CHX treatment, the two alleles
have near-equal frequency (panels C5 and C7, respectively).
In contrast, with transcripts containing long 3′UTR, no
change was detected upon CHX treatment using Surveyor as-
say (Fig. 3B, lanes 13–16). Consistently, sequencing of the
PCR products revealed that the two alleles were equally rep-
resented in the presence or absence of CHX (Fig. 3C, panels
C2, C4, C6, C8). Therefore, we conclude that the nonsense
1504C>T mutation leads to isoform-specific NMD in the
patient cells and affects only the cytoplasmic short-3′UTR
isoform, but not the nuclear long-3′UTR isoform.
Mapping the RNA–protein contacts of the 65K C-
terminal RRM using NMR
The crystal structure of the 65K C-RRM has been reported
earlier (Netter et al. 2009). This study revealed that the
RRM adopts a classic RRM fold with a βαββαβ topology,
but with an additional N-terminal extension that stabilizes
the domain. To understand the structural basis of the re-
duced binding of the U12 snRNA on the P474T mutant,
we first solved the solution structure of the wild-type C-
RRM domain (381–516), and analyzed the RNA–protein in-
teractions by NMR spectroscopy. The NMR structure of the
wild-type C-RRM revealed a canonical RRM fold with a flex-
ible C-terminal region (Fig. 4A,B). The globular domain of
C-RRM is similar to the published crystal structure (PDB
ID: 3EGN) with backbone global displacements below 1 Å
for the majority of the secondary structures, but shows
some differences in the loop regions and around helices αII
and 310II. The largest difference was observed for the loop
between β2 and β3 strands, where two backbone nitrogen
assignments are missing (Fig. 4C). The 15N backbone
FIGURE 2. 65K mutants form di-snRNPs with reduced efficiency. (A)
HeLa cells were transfected with plasmids for expressing V5-tagged 65K
protein (WT, P474T, or R502X) or empty vector. After cell lysis, immu-
noprecipitation was carried out using either anti-V5 antibody or anti-
FLAG antibody as a control for nonspecific binding and co-immuno-
precipitation of U11 and U12 snRNAs was analyzed by northern blot.
Protein and mRNA level measurements of exogenous 65K by western
blotting and RT-PCR, respectively, were carried out from experiments
run parallel with the co-IP samples. (B) Quantification of the northern
(co-IP) and western blot data from A. U11 and U12 co-IP data were de-
rived from three independent experiments which were normalized
within each experiment by setting the mean U11 + U12 value of the
WT co-IP reaction to one. V5-tagged protein level measurements
were similarly derived from three independent experiments and nor-
malized first using GAPDH signal, then by setting the WT value to
one. Significance levels are indicated (ns: P > 0.05, [∗] P≤ 0.05, [∗∗]
P≤ 0.01, [∗∗∗] P≤ 0.001).
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relaxation measurement confirms the flexibility of the C-ter-
minal region as indicated by longer T2 relaxation times and
smaller heteronuclear NOEs (Supplemental Fig. S4). The
largest difference between the crystal and NMR structures
was observed at the C terminus. Whereas the crystal structure
was modeled until residue 506, the C-terminal flexible region
of the NMR structures starts around residue 502 as suggested
by the 15N relaxation data.
In the presence of the U12 RNA oligo (1:1 RNA:protein
molar ratio), 15 residues showed significant chemical shift
perturbation (Fig. 5A,B; Supplemental Table 1). In addition,
the signals were not detectable or traceable for 16 residues in
the [1H, 15N]-HSQC spectrum of 65K C-RRM in the pres-
ence of RNA, presumably due to the exchange broadening.
Consistent with a mode of RNA binding characteristic of ca-
nonical RRMs, many of the residues on the RRM’s β-sheet
surface (β1–β4) responded to RNA binding, including most
of the residues belonging to the highly conserved RNP2
and RNP1 motifs on β1 and β2, respectively. This was also
in line with the positively charged surface of the NMR struc-
ture, which is likely to interact with the negative surface of the
RNA (Fig. 5D). Furthermore, an earlier study reported that
Y423A and Y423F mutations in RNP2 and a K466Q muta-
tion in RNP1 completely abolish the binding of 65K C-
RRM to RNA (Netter et al. 2009). Consistently, these residues
show either significant change in chemical shifts (Fig. 5A,B:
423Y) or disappear in the presence of RNA (Fig. 5B: 466K)
in our NMR experiment. Changes were also seen in the non-
canonical N-terminal extension (Fig. 5B, residues 388–411),
which provides stabilization and is required for enhancing
the RNA binding affinity (Netter et al.
2009). Interestingly, residues 502R and
504A, both of which are deleted by the
R502Xmutation, were among the residues
showing notable chemical shift changes
(Fig. 5B,C). As residues 507–517 are dis-
posable for RNA binding (Netter et al.
2009), the critical residue(s) accounting
for the complete loss of RNA binding
seen with the R502X mutant are expected
to lie within the range 502–506.
Structural effects of the P474T
mutation
In the structure of the 65K C-RRM, pro-
line 474 is located in a turn connecting β3
and αIV (Fig. 4A). Based on the position
of this residue, we predicted that the
P474T mutation might affect the folding
of the RRM domain. Indeed, the HSQC
spectrum of the P474T mutant indicates
that the well-folded globular structure of
the wild-type protein is no longer pre-
sent, with severe line-broadening of
signals, presumably due to slow conformational exchange be-
tween the partially folded and unfolded states (Fig. 6A). The
mutant also slowly precipitated after cleavage of the tandem
fusion protein of maltose binding protein and SUMO
domain (Guerrero et al. 2015). In contrast, the HSQC spec-
trum of the R502X mutant revealed that this mutant retains
the well-folded structure of the wild-type protein (Fig. 6B).
To confirm the NMR result with the P474Tmutant, we first
used differential scanning fluorimetry (DSF) to analyze the
thermal stability of the untagged WT and P474T RRM in
the presence and absence of RNA ligand (Fig. 6C). In the ab-
sence of RNA, we measured a melting temperature of 37°C for
thewild-type RRM.When the proteinwas preincubated with a
10-fold molar excess of the U12 RNA oligo, the melting tem-
perature shifted to 67°C, showing that RNA binding leads to
significant thermal stabilization. Compared to WT, the melt-
ing curve of the P474Tmutant assumed a very different shape,
showing high fluorescence already at low temperatures and
essentially lacking a clear unfolding transition, supporting
the molten globule-like state of the mutant. Little change
was observed upon addition of RNA ligand. The behavior of
the P474T mutant in the assay suggests that this mutation
has a destabilizing effect on the fold of the domain.
However, the finding that P474T is still able to bind RNA,
albeit with lower affinity compared to WT, suggests that the
mutant retains crucial elements needed for RNA binding.
To more carefully investigate the structural effects of the
P474T mutation, we recorded the NMR spectrum of the
P474T mutant with and without RNA ligand (Fig. 6D).
The severely broadened NMR signals of the P474T mutant
FIGURE 3. Nonsense 65K transcripts with short 3′UTR are targeted to the NMD pathway. (A)
Schematic presentation of the 65K long-3′UTR and short-3′UTR isoforms, with the location of
the P474T and R502X mutations and the primers used in 2B and 2C indicated. (B) Surveyor nu-
clease digestion of short-3′UTR and long-3′UTR RT-PCR products from DMSO- or CHX-treat-
ed lymphoblastoid cell lines. RT-PCR was carried out using primers shown in Figure 2A, followed
by reannealing of the PCR products and digestion with the mismatch-specific Surveyor nuclease.
(C) Sanger sequencing of the short-3′UTR and long-3′UTR RT-PCR products from a patient
lymphoblastoid cell line. Arrows indicate the position of the c. 1302C>A and c. 1504C>T
mutations.
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due to slow conformational exchange caused some shifts of
the peaks in the spectrum upon addition of the RNA ligand.
This observation suggests that the P474T mutant retains
some capability to bind RNA, which presumably leads to a
shift in the conformational equilibrium. However, the struc-
ture of the P474T mutant seems to be still a mostly molten
globule-like structure because of the severe line-broadening
of the signals. Unfortunately, it was not feasible to obtain res-
idue specific assignments of the RNA binding sites due to the
low concentration and line-broadening.
DISCUSSION
The RNPC3 gene codes for the U11/U12-65K protein that
connects the individual U11 and U12 snRNPs to form the
U11/U12 di-snRNP necessary for the minor intron recogni-
tion (Frilander and Steitz 1999; Benecke et al. 2005). Earlier
work with RNPC3 has described the compound heterozy-
gous mutations P474T and R502X that are associated with
defects in minor intron splicing, pituitary
hypoplasia and IGHD (Argente et al.
2014). In this work, we have carried out
a detailed mechanistic investigation of
the mutations, showing that they both af-
fect the integrity of the U11/U12 di-
snRNP by destabilizing RNPC3 either at
mRNA or protein level. We find that
the RNPC3 mRNA carrying R502X mu-
tation is primarily targeted by the NMD
machinery in the patient cells, and is ex-
pected to reduce the overall cellular levels
of the U11/U12-65K protein (Argente
et al. 2014). In contrast, the P474Tmuta-
tion leads to a partial defect in the folding
of the C-RRM, a subsequent threefold re-
duction in binding to both U12 and
U6atac snRNAs, reduced formation of
the U11/U12 di-snRNP complexes and
reduced stability of the full-length pro-
tein. Together our results suggest that
the combined effect of the reduced levels
of the U11/U12-65K protein and a partial
loss of the binding to the U12 and possi-
bly U6atac snRNAs both contribute to
the pathology of IGHD (Fig. 7).
Furthermore, our data suggest that in
compound heterozygote patients, only
the U11/U12-65K protein with P474T
mutation can support functional interac-
tions between the C-RRM and the U12 or
U6atac snRNAs.
Both the NMR and DSF analyses indi-
cate that the P474T mutation leads to a
partial destabilization of the C-RRM
and a molten globule-like state of this
domain, which then presumably reduces affinity to U12
and U6atac snRNAs. The effect on folding is consistent
with the location of the phylogenetically conserved P474 res-
idue in a turn position connecting β3 and αIV elements of the
C-RRM (Fig. 4A), which is known to be sensitive to suchmu-
tations (Betts and Russell 2003; Argente et al. 2014). In con-
trast, NMR data indicates that the R502X C-RRM is correctly
folded, suggesting that the loss of snRNA binding in our in
vitro experiments is a result of a loss of a critical interaction
between snRNAs and the C-terminal residues of the protein.
In the context of full-length protein, our data suggest that
the folding defect associated with the P474T mutation is re-
versible and restricted to the C-terminal part of the protein.
Specifically, comparison of the co-IP efficiencies with V5-
tagged WT, P474T and R502X 65K proteins revealed that
both mutations lead to reduced overall association with
U11 and U12 snRNPs. Significantly, with the P474T muta-
tion the U11/U12 ratio was equal to that of the WT protein,
while the R502X showed substantially reduced U12 snRNP
FIGURE 4. NMR structure of wild-type 65K C-RRM domain. (A) The solution NMR structure
of wild-type C-RRM. Secondary structure elements are indicated in the figure. The side-chain of
proline 474 is displayed in red by stick model. Residues within the C-RRM core region are shown.
(B) Superposition of the 20 energy-minimized CYANA conformers representing the wild-type
65K C-RRM domain in solution. The locations of the N and C termini are indicated. The location
of proline 474 is indicated in red. Structures are visualized by MOLMOL. (C) Plot of the global
displacement (D(glob)) per residue of backbone heavy atoms (continuous line) and all heavy atoms
(dashed line) of the wild-type 65K C-RRM crystal structure versus the mean NMR structure. The
backbone heavy atoms of the structured region (388–501) were initially superimposed for min-
imal RMSD. Secondary structure is shown above the plot.
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co-IP levels. Together these results suggests that neither one
of the two mutations interferes with the interactions between
65K N-terminal RRM and the U11-59K protein, but only the
P474T supports stable interactions with the U12 snRNA.
Additionally, the identical U11/U12 ratio observed between
WT and P474T mutant co-IP experiments (Fig. 2B) further
suggests that a successful incorporation of the P474T mutant
within the di-snRNP leads to stabilization of the C-RRM,
possibly as a consequence of U12 snRNA binding to the
P474T C-RRM. This interpretation is consistent with the ob-
servations of improved folding of the P474T C-RRM (Fig.
6D) and the stabilization of the WT C-RRM (Fig. 6C) in
the presence of U12 RNA hairpin.
Using patient cell lines, we further demonstrate that the
R502X mutation leads to isoform-specific NMD of the
RNPC3mRNA. Specifically, due to the underlying crossregu-
lation pathway (Verbeeren et al. 2010, 2017), two RNPC3
mRNA isoforms are produced, of which the long-3′UTR iso-
form is retained in the nucleus and thus escapes NMD; how-
ever, the short-3′UTR isoform is efficiently exported to the
cytoplasm and is accessible to the NMDmachinery. As a con-
sequence of NMD, the translational output of the R502X al-
lele is likely to be low or negligible. Given that the P474T
mutation apparently also leads to a faster turnover of the
65K protein (Fig. 2A), it is possible that the 65K protein
with P474T mutation is stable only within the U11/U12 di-
snRNP. Therefore, the disproportionately strong reduction
in the 65K protein levels in addition to the reduced U11/
U12 di-snRNP levels observed earlier in the patient cells
(Argente et al. 2014), could be explained through a concerted
effect of both mutations in reducing the cellular 65K protein
levels.
Even though the primary effect of the R502X mutation is
mRNA decay by the NMDmachinery, this mutation can po-
tentially also delete the C-terminal tail of the 65K protein in
hypothetical cases where subsets of the transcripts escape the
decay pathway. Interestingly, our in vitro binding experi-
ments with the R502X mutant provided the somewhat unex-
pected result that the loss of the C-terminal tail leads to
complete loss of binding between the C-RRM and U12 or
U6atac snRNAs. The position 502 is located at the beginning
of the flexible C-terminal tail of the domain, which is disor-
dered beyond residue 502 and 506 in the NMR and crystal
structures, respectively. Our NMR data on R502X C-RRM
show that this mutation does not have major structural con-
sequences. Rather, our results suggest that residues in the C-
terminal tail provide additional crucial contacts for U12 and
U6atac snRNA binding. Consistently, in our NMR experi-
ment with the WT C-RRM and U12 snRNA stem–loop,
we observed chemical shift changes in residues 502 and
504 (Fig. 5A,B) both of which are evolutionarily conserved
(Argente et al. 2014), suggesting that they are likely candi-
dates contributing to the recognition of the snRNAs.
The model described above does not account for the po-
tential role of the disrupted 65K–U6atac interaction in
IGHD. Consistent with a recent report documenting the in-
teraction between 65K C-RRM and the distal stem–loop of
U6atac snRNA (Singh et al. 2016), our biochemical analysis
confirmed that the 65K C-RRM can indeed bind to U6atac,
but with approximately threefold reduced affinity compared
FIGURE 5. Interactions between wild-type 65K C-RRM domain and
U12 RNA. (A) An overlay of the [1H, 15N]-HSQC spectra of wild-
type 65K C-RRM in the absence (blue) and presence of U12 RNA
(red). The residues with significant chemical shift perturbations
(>0.15) are labeled in both spectra. (B) A plot of chemical shift pertur-
bation versus the residue number. The dashed line represents the thresh-
old used as the criteria for significant chemical shift perturbations. The
residues that could not be unambiguously identified in the [1H, 15N]-
HSQC spectrum of the C-RRM/RNA complex are indicated with aster-
isks in red. The regions of the secondary structures are indicated above
the plot. (C) Chemical shift perturbations are mapped on the wild-type
65K C-RRM structure, where blue color indicates smallest and orange
biggest CSP value. Locations with the missing signals in [1H, 15N]-spec-
trum of the wild-type 65K C-RRM/RNA complex are colored black.
Prolines and other unassigned residues are colored in white. Side-chains
of the residues with larger chemical shift perturbations (>0.15) are dis-
played by stick models. (D) Surface electrostatic potential of wild-type
65K C-RRM is shown as a colored gradient between −10 kbT/e and 10
kbT/e, where kb is Boltzmann’s constant, T temperature, and e elemen-
tary charge. The structures are visualized by MOLMOL.
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to U12 snRNA. Furthermore, we documented a similar ad-
ditional threefold reduction in the U6atac snRNA binding
with the P474T mutant and a complete loss of binding
with R502X. Currently, little is known about the functional
relevance of the 65K–U6atac interaction. The 3′ end of
U6atac, which includes the 65K-binding stem–loop, has
been demonstrated to play a role in guiding U6atac snRNA
to the minor spliceosome (Dietrich et al. 2009). Although
U6atac snRNA can be pulled down with 65K from HeLa
cell lysate (Singh et al. 2016), it is not known if the 65K pro-
tein associates with the U4atac/U6atac.U5 tri-snRNP or
whether, in addition to the A complex, it is present in later
spliceosomal complexes. Interestingly, analysis of a zebrafish
65K mutant revealed an accumulation of a slow-migrating
complex containing U12, U5, and U6atac snRNAs, leading
the authors to suggest an additional role for 65K in the later
stages of the splicing process, such as spliceosome disassem-
bly or recycling (Markmiller et al. 2014). Whether such a
function would be conserved in human
cells remains to be determined. The
65K-binding U6atac stem–loop appears
to be conserved between zebrafish and
human; however, it is unknown if the
observed accumulation of a late-stage
splicing complex is related to the 65K–
U6atac interaction. Nevertheless, it is
possible that IGHD mutations may
have an additional effect during the later
stages of splicing in addition to intron
recognition. A hypothetical exchange in
interactions from U12 to U6atac snRNA
could expose the P474T C-RRM to an
additional round of unfolding and fold-
ing, which could in turn have down-
stream consequences in the kinetics of
spliceosome assembly and/or the stabil-
ity of the protein.
Ultimately, the reduced formationand/
or stability of the di-snRNP leads to defec-
tive recognition of U12-type introns, re-
sulting in defects in U12-type intron
splicing. Indeed, RNA-seq analysis of pa-
tient blood cells revealed widespread
splicing defects (Argente et al. 2014).
Significantly, in addition to the expected
intron retention events, a substantial
number of cryptic splice site activation
in genes containing U12-type introns
weredetected. This suggests that impaired
recognition of U12-type introns is one of
the outcomes of the IGHD mutations.
However, it does not rule out that later
steps of the spliceosome assembly pro-
cess, due to defects in the putative 65K–
U6atac interaction, could also be affected.
Similar molecular defects as those reported here are
thought to underlie another congenital human disease,
MOPD1, which is caused by mutations in U4atac snRNA
(Edery et al. 2011; He et al. 2011). Akin to the impairment
of the U11/U12-65K–RNA interaction in IGHD, many of
the disease-causing alleles of U4atac snRNA were shown to
disrupt a crucial RNA–protein interaction between the tri-
snRNP specific 15.5K protein (Snu13) and the 5′ stem–
loop of U4atac snRNA (Jafarifar et al. 2014). This binding
defect and its downstream effects on the binding of other
proteins lead to a further defect in the association of U5
snRNP to the U4atac/U6atac di-snRNP and ultimately the
formation of the U4atac/U6atac.U5 tri-snRNP complex.
Thus, both diseases compromise the integrity of a minor spli-
ceosome-specific snRNP complex, either U11/U12 di-
snRNP or U4atac/U6atac.U5 tri-snRNP, as a consequence
of an impaired RNA–protein interaction. The molecular level
difference between the two diseases is that, whereas IGHD
FIGURE 6. Stability and folding properties of 65K C-RRM and its P474T and 502X variants. (A)
An overlay of the [1H, 15N]-HSQC spectra of the wild-type 65K C-RRM (blue) and P474T 65K C-
RRM (pink). (B) An overlay of the [1H, 15N]-HSQC spectra of the wild-type 65K C-RRM (blue)
and R502X 65K C-RRM (green). (C) Differential scanning fluorimetry analysis of wild-type and
P474T-mutant RRM domain. Melting curves of untagged wild-type and P474T-mutant RRM
were obtained in the absence or presence of U12 RNA oligonucleotide by heating the proteins
or protein–RNA complexes in the presence of SYPRO Orange and recording the fluorescence
of the dye as a function of temperature. (D) An overlay of the [1H, 15N]-HSQC spectra of 65K
C-RRM (P474T) in the absence (pink) and presence of RNA (black).
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results from defects in intron recognition, MOPD1 muta-
tions impair the later stages of the minor spliceosome assem-
bly. Presently, it is not known if this molecular level
difference leads to the dramatic difference in severity between
the two diseases: Whereas IGHD is a mild disease, mainly af-
fecting pituitary development and postnatal growth, MOPD1
is usually a very severe disorder causing a number of develop-
mental abnormalities and death at an early age, although
milder cases have also been reported (Abdel-Salam et al.
2016; Krøigård et al. 2016). Presumably, the splicing defects
in IGHD are largely tolerated in other tissues but not in the
developing pituitary gland. Understanding the precise path-
ways involved in both diseases would require detailed inves-
tigations using animal models.
MATERIALS AND METHODS
Protein expression and purification of GST-tagged
proteins
GST-tagged proteins used for in vitro binding assays were expressed
in E. coli Rosetta (DE3)pLysS cells. After 3 h induction with 0.5 mM
IPTG at 37°C, cells were harvested by centrifugation, resuspended in
lysis buffer (50 mMTris–HCl, 150 mMNaCl, 5 mMDTT, pH 8.0 +
1× Roche cOmplete protease inhibitor cocktail) and lysed by sonica-
tion. After centrifugation to pellet cell debris, the GST-tagged fusion
proteins were purified from the lysate using glutathione agarose
(Thermo Scientific) according to the manufacturer’s instructions.
Purified protein was concentrated and buffer-exchanged to 20 mM
HEPES–KOH, 100 mM KCl, 1.5 mM MgCl2, 5% glycerol, pH 8.0.
Cloning, protein expression, and purification
for NMR studies
The coding sequence amplified from plasmid pHAT2-65K-C-RRM
using the two oligonucleotides, I693: 5′-TGAGGATCCGATGAAAT
GCCTTCAGAATG and I710: 5′-GTGGTACCTTACTTTCTTTTT
CCTTCCTTAG, was cloned between BamHI and KpnI of
pHYRSF53 vector (Addgene #64696), resulting in pBHRSF109
bearing H6-SMT3-C-RRM381-516. P474T variant was constructed
with the same oligonucleotide but using the plasmid containing
the mutant as the template and cloned into pLJSRSF7 (Addgene
#64693), resulting in pBHRSF118 coding the fusion protein of
His6-MBP-SUMO-P474 mutant (Guerrero et al. 2015). The
R502X variant was produced from the plasmid pADHRSF12 bear-
ing H6-SMT3-502X, which was constructed using pHYRSF53, and
two oligonucleotides, I693 and J475: 5′-TGCGGTACCTTAA
GCAAACTGAACCACCATGGG. For NMR studies, doubly [13C,
15N]-labeled U11/U12-65K C-RRM (381–516) was expressed using
E. coli strain ER2566 transformed with pBHRSF109 in the M9 me-
dium, supplemented with 25 µg/mL kanamycin and 15NH4Cl and
13C-glucose as the sole nitrogen and carbon sources. The protein
was purified according to the protocol described in Guerrero et al.
(2015). The purified protein was dialyzed against 20.0 mM sodium
phosphate buffer (pH 6.0) and concentrated to 250 µL. d10-DTT
(1,4-ditrithreitol) (Sigma-Aldrich, CAS No. 302912-05-6) was
added to the buffer to a final concentration of 2.0 mM. The 0.2
mM protein sample of doubly [13C, 15N]-labeled U11/U12-65K
C-RRM (381–516) containing 5% D2O (v/v) was transferred
into a 5.0 mm microcell NMR tube (Shigemi Inc.). The 15N-la-
beled U11/U12-65K C-RRM(381–516) P474T sample was expressed
and purified as described above and concentrated to 250 µL (a fi-
nal concentration of 30 µM). The fractionally [15N, 13C]-labeled
U11/U12-65K C-RRM(381–501) 502X mutant sample was expressed
and purified as described above except for the M9 medium that
contained 20% 13C-D-glucose and 80% natural isotope abundance
D-glucose (w/w), and 100% 15NH4Cl as sole nitrogen and carbon
sources, and concentrated to 250 µL with the final concentration
of 88 µM.
FIGURE 7. A model for molecular defects in isolated growth hormone
deficiency with 65Kmutations. IGHD patients are compound heterozy-
gous for two mutations, P474T and R502X, which either destabilize the
65KmRNA through nonsense-mediated decay (R502X) or lead to mis-
folding and presumably increased decay of the 65K protein (P474T).
Due to structural instability and the resulting U12 snRNA binding
defect, the P474T mutant forms U11/U12 di-snRNPs with reduced ef-
ficiency compared to the WT protein. However, the mutant may be sta-
bilized upon incorporation into the U11/U12 di-snRNP complex,
allowing formation of stable di-snRNPs. Reduced level of the U11/
U12 di-snRNP causes defects in intron recognition and U12-type intron
missplicing. Through unknown mechanisms, this leads to impaired de-
velopment of the pituitary gland.
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Electrophoretic mobility shift assay
RNA–protein complexes were formed by incubating ∼1000 cpm
(∼5 nM) of [γ-32P]-ATP-labeled RNA oligo with different concen-
trations of GST-tagged 65K C-RRM (WT, P474T, or R502X) in a to-
tal volume of 10 µL. RNA oligonucleotides used in the assay (U12,
U6atac, control) were bought from Sigma-Aldrich and are listed in
Supplemental Table 2. Gel analysis of either untreated or heat-dena-
turated and snap-cooled oligonucleotides was used to confirm that
hairpin oligonucleotides do not form dimeric structures. The bind-
ing buffer contained 20 mM HEPES–KOH (pH 8.0), 100 mM KCl,
1.5 mM MgCl2, 5% glycerol, 0.1 µg/µL BSA, 1 µg/µL yeast RNA
(Roche) and 1 U/µL RiboLock RNase inhibitor (Thermo
Scientific). After 1 h incubation on ice, 2.5 µL of 5× loading buffer
(20 mM HEPES–KOH, 100 mM KCl, 1.5 mM MgCl2, 50% [v/v]
glycerol, 0.1% [w/v] bromophenol blue, 0.1% [w/v] xylene cyanol)
was added, and 6 µL of each reaction mixture was loaded onto a 6%
native polyacrylamide gel with 0.5× TBE and 5% glycerol. Gels were
run at 120 V for ∼2 h at 4°C and visualized and quantified using the
FLA-5100 phosphorimager and AIDA image analysis software
(Raytest, Germany). Binding curves were fit to data from three inde-
pendent experiments and dissociation constants determined by
nonlinear regression (one-site specific binding with Hill slope) us-
ing GraphPad Prism 6.
Ultraviolet crosslinking assay
RNA–protein complexes were formed as described above for elec-
trophoretic mobility shift assay, except that 105 cpm of RNA was
used for each sample and BSA and yeast RNA were omitted from
the binding buffer. After incubation, samples were transferred
into the wells of a 96-well plate and UV-irradiated for 10 min on
ice using the UVP CL-1000 Ultraviolet Crosslinker. For each pro-
tein, a “no UV” control was also prepared. After UV or control treat-
ment, samples were digested with 20 µg of RNase A for 15 min at
37°C. Samples were then run on a 12% SDS–PAGE gel and the
gel was visualized using FLA-5100 (Fuji).
Differential scanning fluorimetry
Untagged 65K C-RRM (WT or P474Tmutant) was incubated on ice
at a concentration of 5 µM in buffer 20 mMHEPES–KOH (pH 8.0),
100mMKCl, 1.5mMMgCl2 for 1 h without RNA or in the presence
of a 10-fold molar excess of U12 RNA oligo. After incubation,
SYPRO Orange (Sigma) was added to 25× final concentration.
The samples were then heated from 20°C to 95°C at a rate of
∼1°C/min while measuring fluorescence from the SYPRO Orange
dye using the Roche LightCycler 480 real-time PCR machine (exci-
tation = 483 nm, emission = 568 nm). Protein melting temperature
(Tm) was estimated as the temperature corresponding to the maxi-
mum value of the first derivative of fluorescence with respect to
temperature.
Cell culture and transfection
HeLa cells were cultured in DMEM supplemented with 10% FBS,
1% penicillin–streptomycin and 2 mM L-glutamine. Transfections
were carried out using the Lipofectamine 2000 reagent (Thermo
Fisher Scientific). Lymphoblastoid cell lines derived from two con-
trol individuals and two IGHD patients (Argente et al. 2014) were
cultured in RPMI 1640 with 10% FBS, 1% penicillin–streptomycin
and 2 mM L-glutamine. For the nonsense-mediated decay experi-
ments (Fig. 3), cells were treated with 100 µg/mL cycloheximide
or an equal volume of DMSO for 5 h.
RNA extraction and RT-PCR
Total RNA was extracted from cells using the TRIzol reagent and
treated with RQ1 RNase-free DNase (Promega) to remove potential
genomic DNA contamination. cDNA synthesis was carried out us-
ing the Maxima H Minus Reverse Transcriptase (Thermo Fisher
Scientific) and random primers. For PCRs, either the Phire Hot
Start II or Phusion High-Fidelity DNA polymerase (Thermo
Fisher Scientific) was used. Primers used in RT-PCR are listed in
Supplemental Table 2.
Immunoprecipitation and northern blot
HeLa cells were transfected in six-well plate format with 4 µg of pCI-
neo plasmids expressing V5-tagged full-length 65K (wild-type,
P474T or R502X) or empty vector. Twenty-four hours after trans-
fection, cells were washed with PBS, scraped into ice-cold NP-40 ly-
sis buffer (20 mMHEPES, pH 8.0, 137 mMNaCl, 10% glycerol, 1%
NP-40, 2 mM EDTA, 1× cOmplete protease inhibitor cocktail
[Roche], 1 U/µL RiboLock) and sonicated 5 × 30 sec using a
Bioruptor Twin sonicator (Diagenode). After centrifugation
(16,000g, 15 min) to remove cell debris, 2 µg of anti-V5 tag antibody
(Invitrogen, R96025) or control antibody (anti-FLAG, Sigma
F3165) bound to Dynabeads Protein G (Invitrogen) was added
and incubated with the lysate for 1 h at 4°C with end-to-end rota-
tion. After IP, beads were washed 3× with lysis buffer, followed by
proteinase K digestion, phenol:chloroform extraction and ethanol
precipitation. For input samples, RNA was extracted from 1/25 vol-
ume of the pre-IP lysate.
For northern blot, samples were run on an 8% urea–polyacryl-
amide gel and transferred onto Hybond-XL nylon membrane (GE
Healthcare) using an Owl semi-dry blotter. Prehybridization, hy-
bridization, and washes were done as described by Tarn and Steitz
(1996b), except that LNA oligonucleotides U11-6L and U12-9L
(Supplemental Table 2) were used as probes and hybridization
was carried out at 45°C overnight. Northern blots were visualized
and quantified using the FLA-5100 phosphorimager and AIDA im-
age analysis software (Raytest, Germany).
Western blotting
Total protein (10 µg) was run on 10% SDS–PAGE gel and trans-
ferred onto Hybond-P membrane (GE Healthcare). Membranes
were incubated with anti-V5 tag (Invitrogen, R96025) or anti-
GAPDH (Cell Signaling 14C10) antibody, followed by HRP-conju-
gated secondary antibodies (NA931 and NA934, GE Healthcare).
Chemiluminescence was detected using the LAS-3000 imager
(Fuji). Blots were quantified using the Aida software (Raytest,
Germany) and V5-65K signal was normalized to GAPDH signal.
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Surveyor assay
65K short-3′UTR and long 3′UTR isoforms were amplified using
isoform-specific exon-spanning primers (65K-long-R or 65K-
short-R) and a common forward primer (65K-ex11-F;
Supplemental Table 2) using cDNA from cycloheximide or
DMSO-treated lymphoblastoid cell lines as a template. PCR prod-
ucts were column-purified, re-annealed to themselves to form
homo- and heteroduplexes and digested with Surveyor nuclease ac-
cording to the instructions from the Surveyor Mutation Detection
Kit (IDT). Digestion products were analyzed by agarose gel electro-
phoresis. Sanger sequencing of the PCR products (Fig. 3C) was car-
ried out using primer 65K-ex11-F.
NMR spectroscopy
All NMR experiments were carried out on Bruker 600 MHz or 850
MHz Avance III HD NMR spectrometers equipped with a cryogen-
ically cooled TCI probe head. NMR spectra were recorded at 298.3K
or 303.3K. For the sequential backbone assignment, the following
NMR experiments were recorded: [1H, 15N]-HSQC, HNCA,
HNCACB, CBCA(CO)NH, HNCO, HN(CA)CO, CON, CACO
(Sattler et al. 1999; Kostic et al. 2002; Bermel et al. 2005). The ali-
phatic side-chain assignment was carried out using [1H, 13C]-
HSQC, (H)CCCONH, H(CCO)NH, HBHACONH, HCCH-
COSY, HCCH-TOCSY and 15N-edited [1H, 1H]-NOESY spectra.
The assignments for the aromatic side-chains were based on the
spectra of CBCGCDHD, CBCGCDCEHE and 13C-edited [1H,
1H]-NOESY. NMR spectra were processed using Bruker Topspin
3.2. The chemical shift assignment was carried out using CcpNmr
Analysis 2.4.1 software (Vranken et al. 2005).
15N NMR relaxation measurements
For backbone dynamics analysis, the longitudinal (T1) and trans-
verse (T2) relaxation rates and heteronuclear
15N{1H}-NOEs for
backbone 15N atoms were determined at 298 K using the well-estab-
lished NMR pulse sequences described previously (Kay et al. 1989;
Barbato et al. 1992). T1(
15N) and T2(
15N) relaxation times were de-
termined using the following delay times: 10, 50, 100, 200, 300, 500,
800, 1000, 1200, and 2000 msec for T1 and 16, 64, 96, 128, 156, 196,
224, and 256 msec for CMPG pulse train with 1.0 msec interval for
T2 relaxation rates, respectively. Relaxation rates were obtained by
fitting a single exponential decay to peak intensity values: I(t) = I0
× exp(−t/T1) or I0 × exp(−t/T2), where I(t) is the peak volume at
a time t. Heteronuclear 15N{1H}-NOEs were obtained with a relax-
ation delay of 5 sec with or without saturation of protons.
Heteronuclear 15N{1H}-NOEs (η) were derived from the volumes
of the HSQC peaks using the equation of η = I/I0. The relaxation
data were processed and analyzed using Bruker Dynamic Center
software (Version 2.1.8).
NMR structure determination
Upper distance restraints were obtained from NOE intensities
from three-dimensional 15N- or 13C-edited [1H, 1H]-NOESY spec-
tra with a 75-msec mixing time for NOE building up. The
NMR solution conformers were generated using CYANA 3.97
software based on the automated NOESY cross-peak assignments
(Güntert et al. 1997; Güntert 2004, 2009) and dihedral angle
constraints generated using TALOS-N software (Shen and Bax
2013). The restraint energy minimization of the final 20 best con-
formers was performed using AMBER 14 (Cornell et al. 1995). The
structure validation was performed using PSVS 1.5. (Bhattacharya
et al. 2007). The structures were visualized with MOLMOL
(Koradi et al. 1996), which was also used for calculation of the elec-
trostatic surface potential. The final structural statistics are shown
in Table 1.
TABLE 1. Experimental data for the NMR structure calculation
and the structural statistics for the 20 energy-minimized
conformers of wild-type 65K C-RRM
Completeness of resonance assignments (%)a
Backbone 98.8
Side chain 94.0
Aromatic 97.0
Distance restraints
Total 2501
Sequential (|i− j|≤ 1) 1283
Medium range (1 < |i− j| < 5) 476
Long range (|i− j|≥ 5) 742
Dihedral angle restraints
No. of restraints per residue 18.4
No. of long-range restraints per residue 5.5
Residual restraint violations
Average no. of distance violations per structure
0.1–0.2 Å 5.75
0.2–0.3 Å 0
>0.3 Å 0
Average no. of dihedral angle violations per structure
>1° 0
Model qualityb
Rmsd backbone atoms (Å) 0.5
Rmsd heavy atoms (Å) 1.0
Rmsd bond lengths (Å) 0.014
Rmsd bond angles (°) 2.1
Ramachandran statisticsb
Molprobity
Most favored regions (%) 94.8
Allowed regions (%) 5.0
Disallowed regions (%) 0.3
Global quality scoresb (raw/Z score)
Verify3D 0.41/−0.80
ProsaII 0.80/0.62
PROCHECK (φ-ψ) −0.41/−1.30
PROCHECK (all) −0.43/−2.54
MolProbity clash score 1.73/1.23
Model contents
Ordered residue ranges 388–501
Total no. of residues 136
BMRB accession number 34155
PDB ID code 5OBN
aCalculated excluding N-terminal, Lys, amino and Arg guanido
groups, hydroxyls of Ser, Thr and Tyr, carboxyls of Asp and Glu,
and nonprotonated aromatic carbons. Backbone includes HN, Hα,
N, C′, Cα, and Cβ atoms.
bCalculated by using PSVS version 1.5 (Bhattacharya et al. 2007).
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Protein–RNA interaction by chemical shift
perturbation
For the RNA interaction studies, an equimolar protein–RNA (U12)
solution was prepared and transferred into a siliconized 5 mm sym-
metrical microcell NMR tube (Shigemi Inc.). Unlabeled RNA U12
(CCCGCCUACUUUGCGGG) oligonucleotide was purchased
from Sigma-Aldrich. [1H, 15N]-HSQC spectrum of the protein–
RNA solution was recorded and overlaid with the spectrum of the
U11/U12-65K C-RRM protein for the comparison. The chemical
shift perturbations (CSPs) were calculated using the equation CSP
(p.p.m.) = [(Δ1H)2 + 0.157 × (Δ15N)2]1/2 between a peak in the
HSQC spectrum of the free C-RRM protein and the nearest shifted
peak in the HSQC spectrum of the protein–RNA complex. CSPs
were not calculated for the peaks that are apparently disappeared
in the protein–RNA spectrum but marked.
SUPPLEMENTAL MATERIAL
Supplemental material is available for this article.
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